Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0G6VL
|
||||
Former ID |
DAP001427
|
||||
Drug Name |
Sarpogrelate
|
||||
Synonyms |
Sarpogrelate [INN]; Sarpogrelate (INN); Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Hypoglycemic Agents
|
||||
Structure |
Download2D MOL |
||||
Formula |
C24H31NO6
|
||||
InChI |
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
|
||||
InChIKey |
FFYNAVGJSYHHFO-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 125926-17-2
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
5591034, 8153172, 14783045, 29224222, 50070654, 50112742, 57322632, 79008657, 85209566, 92729646, 94569069, 96025193, 103237767, 103815251, 103991695, 104308442, 117548157, 117875099, 124893325, 125728337, 126682430, 127841655, 131846430, 134338631, 134487767, 135150583, 135650981, 137010132, 143372103, 166231393, 172918722, 174006666, 174549251, 179149746, 184546009, 223656940, 226433009, 251888873, 252356575, 252391244
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [537172], [537535], [538037] | |
PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
References | |||||
Ref 535855 | A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs. Yakushigaku Zasshi. 2003;38(1):93-105. | ||||
Ref 539330 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 210). | ||||
Ref 537172 | Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats. Eur J Pharmacol. 2009 Jul 1;614(1-3):122-7. Epub 2009 Mar 24. | ||||
Ref 537535 | Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30. | ||||
Ref 538037 | Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy. Nephron. 1997;76(2):227-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.